63
https://pubmed.ncbi.nlm.nih.gov/38116423
A new series of 3H-pyrido[1,2-c]pyrimidin-3-one derivatives have been discovered as potential and orally bioavailable MAT2A inhibitors for the treatment of MTAP-deleted tumors, with compound 30 showing superior in vivo potency compared to the current clinical compound AG-270.